DCM
CTIC

DAFNA Capital Management’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

DAFNA Capital Management’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-319,538
Closed -$3.93M – 96
2015
Q4 		$3.93M Buy
+319,538
New +$4.27M 3.5% 6
2015
Q1 		– Sell
-142,500
Closed -$3.36M – 83
2014
Q4 		$3.36M Buy
+142,500
New +$3.29M 2.66% 12

Other funds holding CTIC

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

DAFNA Capital Management's CTIC Position: Q1 2016 in Review

DAFNA Capital Management sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q1 2016, closing a stake of 319,538 shares — an estimated $3.93M sold.

DAFNA Capital Management first reported a position in CTIC in Q4 2014 and held it in 2 quarters. The position peaked at $3.93M in Q4 2015. 80 funds tracked by Wall St. Rank hold CTIC as of Q1 2016.

  • DAFNA Capital Management reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q1 2016 after selling out during the quarter.
  • DAFNA Capital Management sold 319,538 CTI BioPharma Corp. (DE) Common Stock shares in Q1 2016, an estimated $3.93M.
  • DAFNA Capital Management first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2014 and held it in 2 quarters.
  • DAFNA Capital Management's CTI BioPharma Corp. (DE) Common Stock position peaked at $3.93M in Q4 2015.
  • 80 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q1 2016.

Based on DAFNA Capital Management's 13F filing for Q1 2016, filed 16 May 2016.